ANI PHARMACEUTICALS, INC (ANIP)

Every figure this model derived for ANIP, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 16,475,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 360,212,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 825,433,000 AssetsCurrent 2026-06-30
current liabilities 283,655,000 LiabilitiesCurrent 2026-06-30
equity 597,212,000 StockholdersEquity 2026-06-30
interest expense 31,284,000 InterestExpenseDebt 2026-06-30
ocf 189,466,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 978,379,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 41,056,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ANIP on one particular measure came for.

RatioValue
cash operating margin28.33
current ratio2.91
current ratio reported2.91
deferred revenue growth-49.04
dilution pct9.89
ebit yoy889.89
fcf margin17.68
growth cv0.52
interest cover4.81
operating margin15.37
owner earnings margin13.49
revenue growth30.9
revenue growth per share19.12
roic22.05
rule of 4046.27
sbc pct revenue4.2

What to be careful about

What this model itself distrusts about ANIP's figures. Written by the derivation as it ran, not added afterwards.